BIONEWS
Perrigo's 'personal conduct' exit, and the disclosure gap it leaves behind
Perrigo's board named the sanction for its ousted CEO but not the standard. For mid cap pharma governance, that asymmetry is the actual story.
Perrigo's board named the sanction for its ousted CEO but not the standard. For mid cap pharma governance, that asymmetry is the actual story.
Perrigo's board removed its chief executive on June 8 over "certain personal conduct" the directors deemed inconsistent with the company's Code of Conduct and core values. What the board did not disclose is what that conduct was. The company named the sanction, then closed the file. For investors, employees, and anyone tracking mid-cap pharma leadership, that gap is the actual story.
The Perrigo press release issued June 8 was explicit on one point and silent on another. Patrick Lockwood-Taylor, who had been president, CEO, and a director, was out effective immediately. The board's reasoning, as written, was that "certain personal conduct" by Lockwood-Taylor was inconsistent with the company's Code of Conduct and core values. The board was equally explicit that this conduct did not involve Perrigo's business, strategy, operations, financial reporting, or results. That second disclosure is doing real work: it tells shareholders the exit is not a financial restatement in disguise. It also draws a hard line around what the company will not say.
The chosen phrasing, "resignation," sits next to the chosen ground, "personal conduct inconsistent with the Code." Read together, they describe a board-determined exit that the company is framing as voluntary, governed by internal standards the public cannot see. The company's statement on what it will not say is the most important disclosure it did not make.
For comparison, when a CEO exits over a financial reporting issue, the disclosure machinery is well understood. A 10-Q explains the restatement. A Form 8-K, or, for Perrigo, a Form 6-K as an Irish-domiciled foreign private issuer, names the triggering event, the accounting implications, and any material weakness disclosures. Investors can read the rule that was broken, the dollar amount in question, and the remediation plan. The standard is public because the standard is shared: GAAP, SEC rules, audit committee charter. There is a comparable public framework for a CEO exit over strategy, where board statements, proxy contests, and shareholder votes give a market-readable signal. There is no comparable public framework for a "personal conduct" exit.
That asymmetry is structural, not a Perrigo quirk. When a board invokes a code of conduct to terminate a CEO, the code itself is typically not public, the criteria for invoking it are not public, and the evidence the board relied on is not public. The company gets the public relations benefit of decisive action. Investors and employees get the binary fact of the exit without the criteria. The accountability runs one way.
Perrigo is a particularly visible case. The company is mid-cap, with a 2026 full-year outlook reaffirmed in its May 6, 2026 Q1 earnings release: All In net sales growth of (5.5)% to (1.5)%, All In adjusted EPS of $2.00 to $2.30, Core net sales growth of (3.0)% to +1.0%, and Core adjusted EPS of $2.25 to $2.55. The leadership change lands on top of a Q1 in which EPS beat consensus (43 cents versus 31 cents) on a revenue miss ($969.2 million versus $1.04 billion), weak cough and cold demand, retailer destocking, and the April 30, 2026 divestiture of the Dermacosmetics branded business for approximately 306 million euros in upfront net proceeds. The press release explicitly lists the impact of the leadership transition on relationships with investors, employees, suppliers, wholesalers, lenders and other stakeholders among its forward-looking risk factors. The board is signaling, in the same document, that the vagueness itself is a known risk to be managed.
The interim CEO is Albert A. Manzone, a Perrigo director since 2022 whose most recent operating role was Deputy CEO of Monte-Carlo Société des Bains de Mer, a luxury hospitality group. His earlier career included time at Whole Earth Brands, Novartis Consumer Health, the Wrigley Company, PepsiCo, and McKinsey. Board chair Orlando D. Ashford said the board has "full confidence" in Manzone and that the company has made significant progress advancing its strategy. The leadership arc matters because Lockwood-Taylor had been CEO for three years and brought prior consumer health experience from Bayer and roughly two decades at Procter & Gamble, per FierceBiotech's coverage. The interim appointment crosses sectors, from luxury hospitality to OTC consumer health, with the board citing a comprehensive search for a permanent successor.
Two practical questions follow for anyone reading this transition. The first is whether the absence of a 6-K or equivalent SEC filing with additional detail is itself the disclosure, or whether the company plans to file one. As of FierceBiotech's June 12 roundup, no such filing had surfaced in the public record. The second is whether proxy disclosures in the next DEF 14A will offer any retrospective clarity on the board's reasoning, or whether the company's posture is to treat this as a fully closed personnel matter.
The precedent being set is not whether Perrigo was right to act. Boards retain the right and the responsibility to remove executives who violate their codes. The precedent is the disclosure architecture around that removal. "Personal conduct" is a category that, by design, can absorb almost any behavior a board finds objectionable. Until the criteria become more legible, every CEO exit filed under that label will be read in the dark. Investors will price transition risk. Employees will read the silence for signals about workplace culture. Governance observers will track the pattern across boards.